Q-omics provides the consensus-scored TEX19 profile across patient tissues and cancer cell-line models. TEX19 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TEX19 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, TEX19 RNA expression shows 10,645 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, HNSC, and TGCT as cancer lineages where TEX19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TEX19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TEX19 survival associations across molecular data types. TEX19 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TEX19 RNA expression–survival associations across cancer types. High TEX19 expression shows unfavorable associations in KIRP, KICH, KIRC and COAD, but favorable associations in LGG and CESC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TEX19 RNA expression.
This table summarizes TEX19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TEX19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TEX19 shows higher tumor expression in HNSC, BLCA, LIHC, KIRP, LUSC and COAD. The HNSC box plot shows higher TEX19 RNA expression in tumor versus normal tissue (log2 FC = +0.321, t-test p < 0.001).
This table shows molecular features associated with TEX19 in patient tissues and cancer cell lines. In patient samples, TEX19 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TEX19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BONE.
